English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Dear Editor,    I am writing to you in order to highlight some miscalculations in an article published in the journal of Technology in Cancer Research &amp; Treatment, entitled; “SRS in Combination with Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases” by Khan, et al. 1  These miscalculations changed the derived conclusion about median survival time, and adverse effects in the selected treatment groups. So, amending these miscalculations may help readers in future research decisions.

SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases